Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method
April 26 2022 - 8:26AM
Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos'' or the
“Company''), a medical technology company focused on developing and
commercializing innovative diagnostic and treatment modalities for
patients with dentofacial abnormalities and/or mild to moderate
obstructive sleep apnea (OSA) and snoring, announced today that
Vivos’ medical integration division will open its third U.S.
multidisciplinary sleep apnea clinic (known as a Pneusomnia Sleep
Center) in May 2022 in Toluca Lake, Calif. The new facility
will join existing Pneusomnia Centers in Del Mar and Modesto,
Calif.
The Center will be a clinician-owned,
Medicare-approved clinic. It will provide a comprehensive array of
services that include The Vivos Method treatment for both adults
and children, mandibular advancement devices, laser treatment, oral
myofunctional therapy, home sleep testing and positive airway
pressure (PAP) services. The Center will be led by Dr.
Jonathan Greenburg, DDS, a nationally renowned expert in dental
sleep medicine and faculty member at The Vivos Institute in Denver,
Colo., and Dr. Michael Marsh, MD, an American Board of Internal
Medicine diplomate who has practiced internal medicine for over 25
years.
“Combining sleep medicine’s various dental and
medical aspects is something that the industry has not yet been
able to accomplish in a scalable manner,” said Dr. Marsh. “Our
Pneusomnia Center will truly be a one-stop, sleep-focused center
for patients in the community to treat their airway issues. Our
mission with opening this practice is to have a profound impact on
the lives of patients and their families through treating OSA’s
root cause once and for all.”
“Over the past 20 years, I have treated
thousands of OSA patients using traditional mandibular advancement
oral appliances. When I came across The Vivos Method, I immediately
knew that the treatment had significant clinical and patient
advantages,” added Dr. Greenburg. “Vivos’ breakthrough technology
and protocols are changing the face of OSA treatment as we know it
today for patients in need all over the country.”
Established in 2021, Vivos’ medical integration
division assists Vivos-trained dental practices in establishing
clinical collaborations with local primary care physicians; sleep
specialists; ear, nose and throat doctors; cardiologists;
pediatricians; pulmonologists and other healthcare providers who
routinely see or treat patients with sleep and breathing
disorders.
The division’s primary objective is to promote
The Vivos Method to medical providers and facilitate the potential
for mild to moderate OSA patients to gain access to the treatment.
Each independent Pneusomnia Center is managed by Vivos under a
management and development agreement, which pays Vivos a percentage
of all net revenue from sleep-related services. Vivos also collects
a development fee for each Pneusomnia Center prior to opening to
assist in establishing operational protocols.
About Vivos
Therapeutics, Inc. Vivos Therapeutics Inc. (NASDAQ:
VVOS) is a medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from dentofacial abnormalities and/or mild to
moderate sleep apnea (OSA) and snoring in adults. The Vivos Method
represents the first clinically effective non-surgical,
non-invasive, non-pharmaceutical and cost-effective solution and
has proven effective in approximately 25,000 patients treated
worldwide by more than 1,450 trained dentists.
Combining proprietary
technologies and protocols that alter the size, shape and position
of the tissues that comprise a patient’s upper airway, The Vivos
Method opens airway space and may significantly reduce symptoms and
conditions associated with mild to moderate OSA, such as lowering
Apnea Hypopnea Index scores. Vivos also markets and distributes
SleepImage diagnostic technology under its VivoScore program for
Home Sleep Testing in adults and children. The Vivos Integrated
Practice (VIP) program offers dentists training and other
value-added services in connection with using The Vivos
Method. For more information, visit
www.vivos.com. Cautionary Note Regarding
Forward-Looking Statements This press release and
statements of the Company’s management made in connection therewith
contain “forward-looking statements” (as defined in Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) concerning future
events, particularly with respect to the public offering described
herein. Words such as “aim”, “may”, “could”, “should”, “expects”,
“projects,” “intends”, “plans”, “believes”, “predicts”,
“anticipates”, “hopes”, “estimates” and variations of such words
and similar expressions are intended to identify forward-looking
statements. These statements involve known and unknown risks and
are based upon several assumptions and estimates, which are
inherently subject to significant uncertainties and contingencies,
many of which are beyond Vivos’ control. Actual results (including,
without limitation, the results of the new Pneusomnia Centers
described herein) may differ materially from those expressed or
implied by such forward-looking statements. Factors that could
cause actual results to differ materially include, but are not
limited to, the risk factors described in Vivos’ filings with the
Securities and Exchange Commission (“SEC”). Vivos’ filings can be
obtained free of charge on the SEC's website at www.sec.gov. Except
to the extent required by law, Vivos expressly disclaims any
obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Vivos' expectations with respect thereto or
any change in events, conditions, or circumstances on which any
statement is based.
Vivos Investor
Relations Contact: Julie GannonInvestor Relations
Officer(303) 859-3847jgannon@vivoslife.com Vivos
Media Relations Contact:Francesca DeMauro / Jenny
RoblesKCSA Strategic Communications(917) 880-9771 / (212)
896-1231fdemauro@kcsa.com / jrobles@kcsa.com
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vivos Therapeutics (NASDAQ:VVOS)
Historical Stock Chart
From Apr 2023 to Apr 2024